Answers are grounded in this paper and cite their sources.
Despite indolent disease and infrequent MYCN amplification, older children with advanced disease have poor survival, without evidence for a specific age cut-off. Our data suggest that AHCT may provide a survival benefit in older children with advanced disease. Novel therapeutic approaches are required to more effectively treat these patients.
No takes yet. Share an insight, caveat, or question.
Mossé et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: